From: Impact of residual urine volume decline on the survival of chronic hemodialysis patients in Kinshasa
Variables | Univariate Analysis | Multivariate Analysis | ||||||
---|---|---|---|---|---|---|---|---|
HR | 95,0%CI | p | Adjusted HR | 95,0%CI | p | |||
Financing (not secured vs yes) | 3.33 | 2.16 | 5.15 | <0.001 | 2.23 | 1.11 | 4.46 | 0.024 |
Weight *(Kg) | 0.98 | 0.96 | 0.99 | 0.005 | 1.02 | 0.99 | 1.04 | 0.179 |
Decline RUV (≥25 vs <25 ml/day/month) | 4.56 | 2.87 | 7.23 | <0.001 | 5.35 | 2.73 | 10.51 | <0.001 |
Hypervolemia (yes vs no) | 2.79 | 1.90 | 4.09 | <0.001 | 2.00 | 1.17 | 3.40 | 0.011 |
ACE inhibitor | 2.53 | 1.71 | 3.74 | <0.001 | 2.48 | 1.40 | 4.40 | 0.002 |
Beta blocker | 2.56 | 1.37 | 4.79 | 0.003 | 4.04 | 1.42 | 11.54 | 0.009 |
Catheter vs AVF | 18.84 | 5.89 | 60.26 | <0.001 | 6.26 | 1.71 | 22.85 | 0.006 |
Weekly hours of HD ≤8 vs ≥12 | 1.56 | 1.06 | 2.31 | 0.024 | 1.70 | 0.91 | 3.17 | 0.095 |
Charlson Index* | 1.08 | 1.01 | 1.15 | 0.022 | 1.01 | 0.94 | 1.09 | 0.812 |
Kaliemia*, mEq/l | 1.17 | 1.02 | 1.35 | 0.027 | 1.12 | 0.92 | 1.35 | 0.272 |
Serum albumine*, g/l | 0.94 | 0.92 | 0.97 | <0.001 | 0.93 | 0.89 | 0.96 | <0.001 |
Hemoglobin*, g/dl | 0.731 | 0.66 | 0.81 | <0.001 | 0.73 | 0.63 | 0.84 | <0.001 |